Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OncoSec Medical Inc ONCSQ

Healthcare Biotechnology
OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec... see more

Recent & Breaking News (GREY:ONCSQ)

OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

PR Newswire May 18, 2023

OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

PR Newswire May 16, 2023

OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

PR Newswire May 16, 2023

OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program

PR Newswire April 27, 2023

OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

PR Newswire April 11, 2023

OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

PR Newswire April 10, 2023

OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO(TM)-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

PR Newswire April 3, 2023

OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022

PR Newswire December 5, 2022

OncoSec Announces Pricing of $3.5 Million Public Offering

PR Newswire November 30, 2022

OncoSec presents encouraging early data with TAVO(TM)-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma

PR Newswire November 15, 2022

OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

PR Newswire November 11, 2022

OncoSec Announces Reverse Stock Split

PR Newswire November 8, 2022

OncoSec Announces Pipeline Prioritization and Workforce Reduction

PR Newswire October 4, 2022

Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research

PR Newswire June 24, 2022

OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research

PR Newswire May 23, 2022

OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer

PR Newswire April 29, 2022

OncoSec Announces Appointment of George Chi as Chief Financial Officer

PR Newswire February 22, 2022

OncoSec Announces Changes to its Board of Directors

PR Newswire December 17, 2021

OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

PR Newswire November 2, 2021

OncoSec Provides Business Update

PR Newswire October 20, 2021